Blurbs

Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Spectrum Pharmaceuticals (SPPI) and Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcus Biosciences (RCUSResearch Report), Spectrum Pharmaceuticals (SPPIResearch Report) and Eli Lilly & Co (LLYResearch Report) with bullish sentiments.

Arcus Biosciences (RCUS)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences today and set a price target of $51.00. The company’s shares closed last Monday at $28.92.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.6% and a 35.8% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $43.57, a 48.7% upside from current levels. In a report issued on November 23, Citigroup also maintained a Buy rating on the stock with a $37.00 price target.

See the top stocks recommended by analysts >>

Spectrum Pharmaceuticals (SPPI)

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Spectrum Pharmaceuticals today and set a price target of $4.00. The company’s shares closed last Monday at $0.48, close to its 52-week low of $0.36.

According to TipRanks.com, Benjamin has 0 stars on 0-5 stars ranking scale with an average return of -10.9% and a 33.8% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Iovance Biotherapeutics, and Allogene Therapeutics.

Spectrum Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $3.00, implying a 575.8% upside from current levels. In a report issued on November 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

Eli Lilly & Co (LLY)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co today and set a price target of $396.00. The company’s shares closed last Monday at $367.64, close to its 52-week high of $369.80.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 8.5% and a 57.7% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Merck & Company, and Replimune Group.

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $383.69, representing a 5.6% upside. In a report issued on November 17, Credit Suisse also initiated coverage with a Buy rating on the stock with a $395.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RCUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More